Patents Assigned to E. R. Squibb & Sons
  • Publication number: 20200231671
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 23, 2020
    Applicant: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. THUDIUM, Mark J. SELBY, Kyra D. ZENS, Mark YAMANAKA, Alan J. KORMAN, Heidi N. LEBLANC
  • Publication number: 20200138945
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: October 11, 2019
    Publication date: May 7, 2020
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20200062848
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
    Type: Application
    Filed: June 21, 2019
    Publication date: February 27, 2020
    Applicant: E.R. Squibb & Sons, L. L. C.
    Inventors: Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Mohan SRINIVASAN, David B. PASSMORE, Haichun HUANG, Haibin CHEN
  • Patent number: 10501556
    Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 10, 2019
    Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.
    Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
  • Patent number: 10448622
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 22, 2019
    Assignees: E. R. Squibb & Sons, L.L.C., Kyowa Hakko Kirin Co., Ltd
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 10441655
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 15, 2019
    Assignees: ONO PHARMACEUTICAL CO., LTD., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20190276539
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Applicant: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. Leblanc
  • Publication number: 20190276538
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Applicant: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. Leblanc
  • Patent number: 10385133
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 20, 2019
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Patent number: 10344089
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 9, 2019
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. LeBlanc
  • Patent number: 10155813
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 18, 2018
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Patent number: 10106615
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: October 23, 2018
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Michelle Kuhne, Peter Brams, Dawn M. Tanamachi, Alan Korman, Josephine M. Cardarelli
  • Patent number: 10076103
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 18, 2018
    Assignees: KYOWA HAKKO KIRIN CO., LTD., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Patent number: 9988453
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 5, 2018
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison J. Witte, Haichun Huang
  • Publication number: 20170369568
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 28, 2017
    Applicant: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David J. King, David B. Passmore
  • Patent number: 9765141
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: September 19, 2017
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David B. Passmore
  • Patent number: 9758593
    Abstract: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from 1B3. Other embodiments are directed toward the antibodies themselves and methods of binding the antibodies.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: September 12, 2017
    Assignees: University of Cincinnati, E. R. Squibb & Sons, L.L.C.
    Inventors: Andrew B. Norman, William J. Ball, Jr., Nils Lonberg, Denise Williams
  • Patent number: 9693539
    Abstract: The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: July 4, 2017
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Daniel K. Rohrer, Nancy Amelia Black, Nils Lonberg
  • Publication number: 20170158767
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
    Type: Application
    Filed: January 23, 2017
    Publication date: June 8, 2017
    Applicant: E.R. Squibb & Sons, L. L. C.
    Inventors: Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Mohan SRINIVASAN, David B. PASSMORE, Haichun HUANG, Haibin CHEN
  • Patent number: 9631025
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: April 25, 2017
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli